266 related articles for article (PubMed ID: 25734936)
1. Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.
Jung KY; Wang H; Teriete P; Yap JL; Chen L; Lanning ME; Hu A; Lambert LJ; Holien T; Sundan A; Cosford ND; Prochownik EV; Fletcher S
J Med Chem; 2015 Apr; 58(7):3002-24. PubMed ID: 25734936
[TBL] [Abstract][Full Text] [Related]
2. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
[TBL] [Abstract][Full Text] [Related]
3. Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function.
Jiang H; Bower KE; Beuscher AE; Zhou B; Bobkov AA; Olson AJ; Vogt PK
Mol Pharmacol; 2009 Sep; 76(3):491-502. PubMed ID: 19498040
[TBL] [Abstract][Full Text] [Related]
4. A novel inhibitor L755507 efficiently blocks c-Myc-MAX heterodimerization and induces apoptosis in cancer cells.
Singh A; Kumar A; Kumar P; Nayak N; Bhardwaj T; Giri R; Garg N
J Biol Chem; 2021 Jul; 297(1):100903. PubMed ID: 34157284
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule modulators of c-Myc/Max and Max/Max interactions.
Berg T
Curr Top Microbiol Immunol; 2011; 348():139-49. PubMed ID: 20680803
[TBL] [Abstract][Full Text] [Related]
6. Targeted Disruption of Myc-Max Oncoprotein Complex by a Small Molecule.
Choi SH; Mahankali M; Lee SJ; Hull M; Petrassi HM; Chatterjee AK; Schultz PG; Jones KA; Shen W
ACS Chem Biol; 2017 Nov; 12(11):2715-2719. PubMed ID: 28976731
[TBL] [Abstract][Full Text] [Related]
7. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.
Clausen DM; Guo J; Parise RA; Beumer JH; Egorin MJ; Lazo JS; Prochownik EV; Eiseman JL
J Pharmacol Exp Ther; 2010 Dec; 335(3):715-27. PubMed ID: 20801893
[TBL] [Abstract][Full Text] [Related]
8. Preferential heterodimeric parallel coiled-coil formation by synthetic Max and c-Myc leucine zippers: a description of putative electrostatic interactions responsible for the specificity of heterodimerization.
Lavigne P; Kondejewski LH; Houston ME; Sönnichsen FD; Lix B; Skyes BD; Hodges RS; Kay CM
J Mol Biol; 1995 Dec; 254(3):505-20. PubMed ID: 7490766
[TBL] [Abstract][Full Text] [Related]
9. New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ.
Beaulieu ME; McDuff FO; Frappier V; Montagne M; Naud JF; Lavigne P
J Mol Recognit; 2012 Jul; 25(7):414-26. PubMed ID: 22733550
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.
Soodgupta D; Pan D; Cui G; Senpan A; Yang X; Lu L; Weilbaecher KN; Prochownik EV; Lanza GM; Tomasson MH
Mol Cancer Ther; 2015 Jun; 14(6):1286-1294. PubMed ID: 25824336
[TBL] [Abstract][Full Text] [Related]
11. Sequence-specific DNA binding by MYC/MAX to low-affinity non-E-box motifs.
Allevato M; Bolotin E; Grossman M; Mane-Padros D; Sladek FM; Martinez E
PLoS One; 2017; 12(7):e0180147. PubMed ID: 28719624
[TBL] [Abstract][Full Text] [Related]
12. The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
Lafita-Navarro MC; Liaño-Pons J; Quintanilla A; Varela I; Blanco R; Ourique F; Bretones G; Aresti J; Molina E; Carroll P; Hurlin P; Romero OA; Sanchez-Céspedes M; Eisenman RN; Delgado MD; León J
J Biol Chem; 2020 Feb; 295(7):2001-2017. PubMed ID: 31919096
[TBL] [Abstract][Full Text] [Related]
13. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation.
Castell A; Yan Q; Fawkner K; Hydbring P; Zhang F; Verschut V; Franco M; Zakaria SM; Bazzar W; Goodwin J; Zinzalla G; Larsson LG
Sci Rep; 2018 Jul; 8(1):10064. PubMed ID: 29968736
[TBL] [Abstract][Full Text] [Related]
14. In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.
Raffeiner P; Röck R; Schraffl A; Hartl M; Hart JR; Janda KD; Vogt PK; Stefan E; Bister K
Oncotarget; 2014 Oct; 5(19):8869-78. PubMed ID: 25326649
[TBL] [Abstract][Full Text] [Related]
15. Crystal Structures and Nuclear Magnetic Resonance Studies of the Apo Form of the c-MYC:MAX bHLHZip Complex Reveal a Helical Basic Region in the Absence of DNA.
Sammak S; Hamdani N; Gorrec F; Allen MD; Freund SMV; Bycroft M; Zinzalla G
Biochemistry; 2019 Jul; 58(29):3144-3154. PubMed ID: 31260268
[TBL] [Abstract][Full Text] [Related]
16. Myc phosphorylation in its basic helix-loop-helix region destabilizes transient α-helical structures, disrupting Max and DNA binding.
Macek P; Cliff MJ; Embrey KJ; Holdgate GA; Nissink JWM; Panova S; Waltho JP; Davies RA
J Biol Chem; 2018 Jun; 293(24):9301-9310. PubMed ID: 29695509
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
18. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
19. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
Gupta K; Anand G; Yin X; Grove L; Prochownik EV
Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model.
Mustata G; Follis AV; Hammoudeh DI; Metallo SJ; Wang H; Prochownik EV; Lazo JS; Bahar I
J Med Chem; 2009 Mar; 52(5):1247-50. PubMed ID: 19215087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
